DrugBiological
VK2735 clinical trials
Also written VK2735.
Keep track of what changes. Save the VK2735 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
8 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses VK2735 is read from its arms, and is right about nine times in ten.
Testing it · 8
- Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)Not yet recruitingPhase 3Viking Therapeutics, Inc.NCT07868939Written as VK2735 Oral
- Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)Not yet recruitingPhase 3Viking Therapeutics, Inc.NCT07868835Written as VK2735
- A Phase 1 Study of VK2735 in Obese Adults Without ComorbiditiesRecruitingPhase 1Viking Therapeutics, Inc.NCT07838740Written as VK2735 Drug
- VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)Active, not recruitingPhase 3Viking Therapeutics, Inc.NCT07104383Written as VK2735
- VK2735 for Weight Management Phase 3Active, not recruitingPhase 3Viking Therapeutics, Inc.NCT07104500Written as VK2735
- VK2735 for Weight Management Phase 2 (Venture Oral Dosing)CompletedPhase 2Viking Therapeutics, Inc.NCT06828055Written as VK2735
- Phase 1 Study to Evaluate the Safety and Tolerability of VK2735CompletedPhase 1Viking Therapeutics, Inc.NCT05203237Written as VK2735
- VK2735 for Weight Management Phase 2CompletedPhase 2Viking Therapeutics, Inc.NCT06068946Written as VK2735